Get the Stockscreener App
3.34
0.30%
0.010
After Hours:
3.34
Trevi Therapeutics Inc stock is traded at $3.34, with a volume of 246.61K.
It is up +0.30% in the last 24 hours and up +5.70% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$3.33
Open:
$3.32
24h Volume:
246.61K
Relative Volume:
0.87
Market Cap:
$241.01M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-10.77
EPS:
-0.31
Net Cash Flow:
$-31.85M
1W Performance:
+1.21%
1M Performance:
+5.70%
6M Performance:
-3.19%
1Y Performance:
+53.21%
1-Day Range:
$3.00
$3.38
1-Week Range:
$2.9395
$3.50
52-Week Range:
$0.97
$4.00
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer - StockTitan
President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 - StockTitan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Lifted by Logos Global Management LP - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Financial Health Report: Trevi Therapeutics Inc (TRVI)’s Ratios Tell a Tale - The Dwinnex
Ally Bridge Group NY LLC Invests $4.40 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Taking the lead: Trevi Therapeutics Inc (TRVI) - SETE News
Rubric Capital Management LP Lowers Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Portage Biotech (PRTG): Wild Ride Continues, But Uncertainty Looms - BP Journal
Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World
UChicago Medicine Patient First in the World to Re | Newswise - Newswise
Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks
UChicago Medicine patient first in the world to receive ulcerative colitis drug since FDA approval - UChicago Medicine
Traws Pharma, Inc. Announces Special Shareholders Meeting Results - StockTitan
Taking a Closer Look At Trevi Therapeutics Inc (TRVI) Following Its Recent Trade - Knox Daily
trivago (NASDAQ:TRVG) Sees Large Growth in Short Interest - Defense World
FDA Approves Tremfya for Ulcerative Colitis - Physician's Weekly
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow
trivago (NASDAQ:TRVG) Short Interest Up 16.9% in August - MarketBeat
Trevi Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($0.11) Per Share (NASDAQ:TRVI) - MarketBeat
Leerink Partnrs Upgrades Trevi Therapeutics (NASDAQ:TRVI) to "Strong-Buy" - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Leerink Partners - Defense World
Trevi Therapeutics CEO sells over $18,000 in company stock - Investing.com
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,219 Shares of Stock - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Leerink Partners - MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - sharewise
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MSN
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $33,162.62 in Stock - MarketBeat
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - Citizentribune
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 – Company Announcement - Financial Times
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - PR Newswire
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from Analysts - Defense World
Trevi Therapeutics shares rise on bullish analyst initiation By Investing.com - Investing.com Canada
Raymond James initiates Trevi Therapeutics at Outperform, sees first-to-market opportunity for Haduvio - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Raymond James - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Raymond James - Defense World
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of Stock - MarketBeat
Trevi therapeutics director Meeker sells shares worth over $13,000 - Investing.com
Trevi Therapeutics to Participate in September Investor and Medical Conferences – Company Announcement - Financial Times
Trevi Therapeutics to Participate in September Investor and Medical Conferences - StockTitan
Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com India
Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com
Trevi Therapeutics executive sells shares worth over $48,000 By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton Acquisition Co. I Upgrades Trevi Therapeutics (NASDAQ:TRVI) to Strong-Buy - Defense World
Trevi Therapeutics Provides Business Updates - GuruFocus.com
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):